That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax ... years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge ...

GSK’s Fundamentals And Financial Position GSK’s revenue has risen at an average annual rate of 7.9% from £24.3 billion in 2020 to £30.3 billion in 2023, aided by its specialty medicines ...

GSK’s London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be ...

In late October, GSK said it would seek expanded regulatory approval for Arexvy for adults aged 50 to 59, based on data from a new Phase 3 study. The shot is currently approved for adults aged 60 ...

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

GSK Chief Commercial Officer Luke Miels said on an earnings call in May that the company remains "very confident" that Arexvy can bring in more than £3 billion in peak annual sales over time.

Shanthi Rexaline GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...